Search

Your search keyword '"Al-Harbi, Talal"' showing total 183 results
Start Over Author "Al-Harbi, Talal"
183 results on '"Al-Harbi, Talal"'

1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Author

Lal, Anoushka P., Foong, Yi Chao, Sanfilippo, Paul G., Spelman, Tim, Rath, Louise, Levitz, David, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas-Robledo, Simón, Moghadasi, Abdorreza Naser, Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, and Van der Walt, Anneke

Published
2024
Full Text
View/download PDF

2. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

Author

Li, Ying, Saul, Alice, Taylor, Bruce, Ponsonby, Anne-Louise, Simpson-Yap, Steve, Blizzard, Leigh, Broadley, Simon, Lechner-Scott, Jeannette, Karabudak, Rana, Patti, Francesco, Eichau, Sara, Onofrj, Marco, Ozakbas, Serkan, Horakova, Dana, Kubala Havrdova, Eva, Grand’Maison, Francois, Alroughani, Raed, Gerlach, Oliver, Amato, Maria Pia, Altintas, Ayse, Girard, Marc, Duquette, Pierre, Blanco, Yolanda, Ramo-Tello, Cristina, Laureys, Guy, Kalincik, Tomas, Khoury, Samia J., Shaygannejad, Vahid, Etemadifar, Masoud, Singhal, Bhim, Mrabet, Saloua, Foschi, Matteo, Habek, Mario, John, Nevin, Hughes, Stella, McCombe, Pamela, Ampapa, Radek, van der Walt, Anneke, Butzkueven, Helmut, de Gans, Koen, McGuigan, Chris, Oreja-Guevara, Celia, Sa, Maria Jose, Petersen, Thor, Al-Harbi, Talal, Sempere, Angel Perez, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Prevost, Julie, Gray, Orla, Castillo-Triviño, Tamara, Macdonell, Richard, Lugaresi, Alessandra, Sajedi, Seyed Aidin, and van der Mei, Ingrid

Published
2024
Full Text
View/download PDF

3. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author

Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, Vukusic, Sandra, Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, and Kalincik, Tomas

Published
2024
Full Text
View/download PDF

4. Clinical presentations, electrophysiologic features, and long-term follow-up in Lambert–Eaton myasthenic syndrome: a series of six patients.

Author

Alhammad, Reem M., Alshamlan, Yafa, Alneseyan, Ruwa, Al-Harbi, Talal M., Alhijab, Ali, and Alanazy, Mohammed H.

Subjects
ACTION potentials, SMALL cell carcinoma, ISOMETRIC exercise, CALCIUM channels, MYONEURAL junction
Abstract

Background: Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the presynaptic neuromuscular junction associated with antibody mediated dysfunction of voltage-gated calcium channels (VGCCs). LEMS can exist as a paraneoplastic syndrome, paraneoplastic-LEMS (P-LEMS), when associated with tumors, most commonly, small cell lung carcinoma (SCLC) or as a non-paraneoplastic condition (NP-LEMS) when no malignancies are detected. Methods: A retrospective chart review was conducted in 3 tertiary hospitals in Saudi Arabia for patients diagnosed with LEMS between January 2010 and January 2020. Patients meeting all the following criteria were included: (1) weakness or fatigability of one or more extremity or oculo-bulbar muscles, (2) 60% or higher increment of compound muscle action potential (CMAP) amplitudes immediately following isometric exercise, and (3) positive serum P/Q type VGCC antibodies. Clinical, laboratory, and electrophysiologic features, as well as radiologic imaging modalities performed for tumor screening were reviewed. Results: The study included six patients diagnosed with LEMS, split evenly between P-LEMS and NP-LEMS. Fatigability, particularly in the lower extremities, and dyspnea on exertion were commonly reported symptoms. Low CMAP amplitudes were more frequently seen in NP-LEMS as compared to P-LEMS when recorded from both abductor pollicis brevis and abductor digiti minimi muscles. An incremental response above 60% in post activation CMAPs was detected at similar rates following variable durations of isometric exercise (10, 15, and 20 s). Tumor types detected in 3 patients with P-LEMS are SCLC, breast carcinoma, colon adenocarcinoma, and prostate acinar adenocarcinoma. Triple malignancy was detected in one patient. Conclusion: This is the first study to describe clinical and electrophysiologic features of LEMS in an Arab ethnic cohort. Early recognition of LEMS has a significant impact on prognosis, especially given the aggressive nature of associated cancers such as SCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

Author

Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva Kubala, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga, Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse, Soysal, Aysun, Vucic, Steve, Grand'Maison, Francois, Izquierdo, Guillermo, Eichau, Sara, Lugaresi, Alessandra, Onofrj, Marco, Trojano, Maria, Marriott, Mark, Butzkueven, Helmut, Kister, Ilya, and Kalincik, Tomas

Published
2020
Full Text
View/download PDF

6. Brain abscess following rituximab infusion in a patient with pemphigus vulgaris.

Author

Al-Harbi, Talal M, Al-Muammar, Shahad A, and Ellis, Ronald J

Subjects
Humans, Brain Abscess, Pemphigus, Antigens, CD20, Immunologic Factors, Magnetic Resonance Imaging, Infusions, Intravenous, Middle Aged, Female, Antibodies, Monoclonal, Murine-Derived, Rituximab, Antigens, CD20, Infusions, Intravenous, Antibodies, Monoclonal, Murine-Derived
Abstract

BackgroundImmunocompromised patients are at increased risk for developing meningitis or, rarely, brain abscess with opportunistic organisms like Listeria monocytogenes.Case reportA 52 year-old Saudi Arabian woman who was diagnosed with pemphigus vulgaris and diabetes and had been on prednisolone and azathioprine for about 4 years. She presented with headache, low-grade fever, and left-sided weakness 2 weeks after receiving the second dose of rituximab infusion. Magnetic resonance imaging revealed an enhanced space-occupying lesion with multiple small cyst-like structures and vasogenic edema in the right temporoparietal area. Her blood culture was positive for Listeria monocytogenes, and a brain biopsy showed necrotic tissues with pus and inflammatory cells. She recovered after a 6-week course of antibiotics with ampicillin and gentamycin.ConclusionsBrain abscess due to Listeria monocytogenes is a risk that should be considered when adding rituximab to the regimen of a patient who is already Immunocompromised.

Published
2015

7. Clinical features and outcome of Guillain–Barre syndrome in Saudi Arabia: a multicenter, retrospective study

Author

Alanazy, Mohammed H., Bakry, Sawsan S., Alqahtani, Afnan, AlAkeel, Norah S., Alazwary, Naael, Osman, Afag M., Mustafa, Rania A., Al-Harbi, Talal M., Abdulmana, Sameeh O., Amper, Aimee C., Aldughaythir, Yousef, Ali, Abdulrahman S., Makkawi, Seraj, Maglan, Alaa, Alamoudi, Loujen, Alsulaiman, Feras, Alabdali, Majed, AlShareef, Aysha A., Abuzinadah, Ahmad R., and Bamaga, Ahmed K.

Published
2021
Full Text
View/download PDF

9. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author

Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, and Vukusic, Sandra

Abstract

High-efficacy disease-modifying therapies have been proven to slow disability accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on disability worsening in paediatric-onset multiple sclerosis, particularly during the early phases, is not well understood. We evaluated how high-efficacy therapies influence transitions across five disability states, ranging from minimal disability to gait impairment and secondary progressive multiple sclerosis, in people with paediatric-onset multiple sclerosis.

Published
2024
Full Text
View/download PDF

11. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, primary, Roos, Izanne, additional, Simpson-Yap, Steve, additional, Malpas, Charles, additional, Sánchez, Marina M, additional, Ozakbas, Serkan, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Patti, Francesco, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Boz, Cavit, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Weinstock-Guttman, Bianca, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Amato, Maria Pia, additional, Karabudak, Rana, additional, Grand’Maison, Francois, additional, Khoury, Samia J, additional, Grammond, Pierre, additional, Lechner-Scott, Jeannette, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Maimone, Davide, additional, Kermode, Allan, additional, Shalaby, Nevin, additional, Pesch, Vincent V, additional, Butler, Ernest, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Mrabet, Saloua, additional, Gerlach, Oliver, additional, Soysal, Aysun, additional, Barnett, Michael, additional, Kuhle, Jens, additional, Hughes, Stella, additional, Sa, Maria J, additional, Hodgkinson, Suzanne, additional, Oreja-Guevara, Celia, additional, Ampapa, Radek, additional, Petersen, Thor, additional, Ramo-Tello, Cristina, additional, Spitaleri, Daniele, additional, McCombe, Pamela, additional, Taylor, Bruce, additional, Prevost, Julie, additional, Foschi, Matteo, additional, Slee, Mark, additional, McGuigan, Chris, additional, Laureys, Guy, additional, Hijfte, Liesbeth V, additional, de Gans, Koen, additional, Solaro, Claudio, additional, Oh, Jiwon, additional, Macdonell, Richard, additional, Aguera-Morales, Eduardo, additional, Singhal, Bhim, additional, Gray, Orla, additional, Garber, Justin, additional, Wijmeersch, Bart V, additional, Simu, Mihaela, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose L, additional, Khurana, Dheeraj, additional, Al-Asmi, Abdullah, additional, Al-Harbi, Talal, additional, Deri, Norma, additional, Fragoso, Yara, additional, Lalive, Patrice H, additional, Sinnige, L G F, additional, Shaw, Cameron, additional, Shuey, Neil, additional, Csepany, Tunde, additional, Sempere, Angel P, additional, Moore, Fraser, additional, Decoo, Danny, additional, Willekens, Barbara, additional, Gobbi, Claudio, additional, Massey, Jennifer, additional, Hardy, Todd, additional, Parratt, John, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

13. An experimental and theoretical study of the hot-carrier energy distribution in VLSI MOSFETs

Author

Al-Harbi, Talal S.

Subjects
621.31042, Components
Abstract

MOSFET devices have, recently, been considered the basic building element in any electronic IC circuit or system. The great advances achieved by modem technologies has made it possible to scale-down considerably the MOSFET device (channel length L smaller than 0.5μm and oxide thickness smaller than 400Å) which appreciably influences the device performance and its operating parameters.

Published
1996

15. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Author

Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Diouf, Ibrahima; Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Horakova, Dana; Havrdova, Eva Kubala; Patti, Francesco; Shaygannejad, Vahid; Ozakbas, Serkan; Izquierdo, Guillermo; Eichau, Sara; Onofrj, Marco; Lugaresi, Alessandra; Alroughani, Raed; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Terzi, Murat; Boz, Cavit; Grand'Maison, Francois; Hamdy, Sherif; Sola, Patrizia; Ferraro, Diana; Grammond, Pierre; Turkoglu, Recai; Buzzard, Katherine; Skibina, Olga; Yamout, Bassem; Gerlach, Oliver; van Pesch, Vincent; Blanco, Yolanda; Maimone, Davide; Lechner-Scott, Jeannette; Bergamaschi, Roberto; Karabudak, Rana; Iuliano, Gerardo; McGuigan, Chris; Cartechini, Elisabetta; Barnett, Michael; Hughes, Stella; Sa, Maria Jose; Solaro, Claudio; Kappos, Ludwig; Ramo-Tello, Cristina; Cristiano, Edgardo; Hodgkinson, Suzanne; Spitaleri, Daniele; Soysal, Aysun; Petersen, Thor; Slee, Mark; Butler, Ernest; Granella, Franco; de Gans, Koen; McCombe, Pamela; Ampapa, Radek; Van Wijmeersch, Bart; van der Walt, Anneke; Butzkueven, Helmut; Prevost, Julie; Sinnige, L. G. F.; Sanchez-Menoyo, Jose Luis; Vucic, Steve; Laureys, Guy; Van Hijfte, Liesbeth; Khurana, Dheeraj; Macdonell, Richard; Gouider, Riadh; Castillo-Trivino, Tamara; Gray, Orla; Aguera-Morales, Eduardo; Al-Asmi, Abdullah; Shaw, Cameron; Deri, Norma; Al-Harbi, Talal; Fragoso, Yara; Csepany, Tunde; Sempere, Angel Perez; Trevino-Frenk, Irene; Schepel, Jan; Moore, Fraser; Kalincik, Tomas, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Diouf, Ibrahima; Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Horakova, Dana; Havrdova, Eva Kubala; Patti, Francesco; Shaygannejad, Vahid; Ozakbas, Serkan; Izquierdo, Guillermo; Eichau, Sara; Onofrj, Marco; Lugaresi, Alessandra; Alroughani, Raed; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Terzi, Murat; Boz, Cavit; Grand'Maison, Francois; Hamdy, Sherif; Sola, Patrizia; Ferraro, Diana; Grammond, Pierre; Turkoglu, Recai; Buzzard, Katherine; Skibina, Olga; Yamout, Bassem; Gerlach, Oliver; van Pesch, Vincent; Blanco, Yolanda; Maimone, Davide; Lechner-Scott, Jeannette; Bergamaschi, Roberto; Karabudak, Rana; Iuliano, Gerardo; McGuigan, Chris; Cartechini, Elisabetta; Barnett, Michael; Hughes, Stella; Sa, Maria Jose; Solaro, Claudio; Kappos, Ludwig; Ramo-Tello, Cristina; Cristiano, Edgardo; Hodgkinson, Suzanne; Spitaleri, Daniele; Soysal, Aysun; Petersen, Thor; Slee, Mark; Butler, Ernest; Granella, Franco; de Gans, Koen; McCombe, Pamela; Ampapa, Radek; Van Wijmeersch, Bart; van der Walt, Anneke; Butzkueven, Helmut; Prevost, Julie; Sinnige, L. G. F.; Sanchez-Menoyo, Jose Luis; Vucic, Steve; Laureys, Guy; Van Hijfte, Liesbeth; Khurana, Dheeraj; Macdonell, Richard; Gouider, Riadh; Castillo-Trivino, Tamara; Gray, Orla; Aguera-Morales, Eduardo; Al-Asmi, Abdullah; Shaw, Cameron; Deri, Norma; Al-Harbi, Talal; Fragoso, Yara; Csepany, Tunde; Sempere, Angel Perez; Trevino-Frenk, Irene; Schepel, Jan; Moore, Fraser; Kalincik, Tomas, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine

Abstract

Background and purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). Methods: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ? 1 year, and Expanded Disability Status Scale (EDSS) score ? 3, with ?1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. Results: Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45–0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41–0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09–1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. Conclusions: DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age., This study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766, 1080518).

Published
2023

16. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Daruwalla, Cyrus, primary, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Havrdova, Eva Kubala, additional, Horakova, Dana, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Duquette, Pierre, additional, Yamout, Bassem, additional, Khoury, Samia J, additional, Sajedi, Seyed Aidin, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Grammond, Pierre, additional, Karabudak, Rana, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Soysal, Aysun, additional, John, Nevin, additional, Prevost, Julie, additional, Spitaleri, Daniele, additional, Ramo-Tello, Cristina, additional, Gerlach, Oliver, additional, Iuliano, Gerardo, additional, Foschi, Matteo, additional, Ampapa, Radek, additional, van Pesch, Vincent, additional, Barnett, Michael, additional, Shalaby, Nevin, additional, D’hooghe, Marie, additional, Kuhle, Jens, additional, Sa, Maria Jose, additional, Fabis-Pedrini, Marzena, additional, Kermode, Allan, additional, Mrabet, Saloua, additional, Gouider, Riadh, additional, Hodgkinson, Suzanne, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Macdonell, Richard, additional, Oreja-Guevara, Celia, additional, Cristiano, Edgardo, additional, McCombe, Pamela, additional, Sanchez-Menoyo, Jose Luis, additional, Singhal, Bhim, additional, Blanco, Yolanda, additional, Hughes, Stella, additional, Garber, Justin, additional, Solaro, Claudio, additional, McGuigan, Chris, additional, Taylor, Bruce, additional, de Gans, Koen, additional, Habek, Mario, additional, Al-Asmi, Abdullah, additional, Mihaela, Simu, additional, Castillo Triviño, Tamara, additional, Al-Harbi, Talal, additional, Rojas, Juan Ignacio, additional, Gray, Orla, additional, Khurana, Dheeraj, additional, Van Wijmeersch, Bart, additional, Grigoriadis, Nikolaos, additional, Inshasi, Jihad, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Fragoso, Yara, additional, Moore, Fraser, additional, Shaw, Cameron, additional, Baghbanian, Seyed Mohammad, additional, Shuey, Neil, additional, Willekens, Barbara, additional, Hardy, Todd A, additional, Decoo, Danny, additional, sempere, Angel Perez, additional, Field, Deborah, additional, Wynford-Thomas, Ray, additional, Cunniffe, Nick G, additional, Roos, Izanne, additional, Malpas, Charles B, additional, Coles, Alasdair J, additional, Kalincik, Tomas, additional, and Brown, J William L, additional

Published
2023
Full Text
View/download PDF

17. Comparative effectiveness in multiple sclerosis: A methodological comparison

Author

Roos, Izanne, primary, Diouf, Ibrahima, additional, Sharmin, Sifat, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamou, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Ramo-Tello, Cristina, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sanchez-Menoyo, Jose Luis, additional, Laureys, Guy, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Al-Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel Perez, additional, Trevino-Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, Malpas, Charles, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

18. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Author

Diouf, Ibrahima, primary, Malpas, Charles B., additional, Sharmin, Sifat, additional, Roos, Izanne, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand'Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner‐Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Kappos, Ludwig, additional, Ramo‐Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sinnige, L. G. F., additional, Sanchez‐Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Gouider, Riadh, additional, Castillo‐Triviño, Tamara, additional, Gray, Orla, additional, Aguera‐Morales, Eduardo, additional, Al‐Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al‐Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Perez Sempere, Angel, additional, Trevino‐Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

19. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

Author

Kalincik, Tomas, Sharmin, Sifat, Roos, Izanne, Freedman, Mark S., Atkins, Harold, Burman, Joachim, Massey, Jennifer, Sutton, Ian, Withers, Barbara, Macdonell, Richard, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trněný, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, McCombe, Pamela, Skibina, Olga, Lechner-Scott, Jeannette, Willekens, Barbara, Cartechini, Elisabetta, Ozakbas, Serkan, Alroughani, Raed, Kuhle, Jens, Patti, Francesco, Duquette, Pierre, Lugaresi, Alessandra, Khoury, Samia J., Slee, Mark, Turkoglu, Recai, Hodgkinson, Suzanne, John, Nevin, Maimone, Davide, Sa, Maria Jose, van Pesch, Vincent, Gerlach, Oliver, Laureys, Guy, Van Hijfte, Liesbeth, Karabudak, Rana, Spitaleri, Daniele, Csepany, Tunde, Gouider, Riadh, Castillo-Triviño, Tamara, Taylor, Bruce, Sharrack, Basil, Snowden, John A., Horakova, Dana, Buzzard, Katherine, Terzi, Murat, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Barnett, Michael, Stewart, Grace, Onofrj, Marco, Izquierdo, Guillermo, Eichau, Sara, Grand'Maison, Francois, Prevost, Julie, Van Wijmeersch, Bart, Amato, Maria Pia, Shaygannejad, Vahid, Boz, Cavit, Bolaños, Ricardo Fernandez, Soysal, Aysun, Ramo-Tello, Cristina, Solaro, Claudio, Gobbi, Claudio, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Deri, Norma, Saladino, Maria Laura, Cristiano, Edgardo, Rojas, Juan Ignacio, Vrech, Carlos, Shaw, Cameron, Shuey, Neil, Boggild, Mike, Tan, Ik Lin, Hardy, Todd, Decoo, Danny, Moore, Fraser, Oh, Jiwon, Lalive, Patrice, Ampapa, Radek, Petersen, Thor, Oreja-Guevara, Celia, Perez Sempere, Angel, Dominguez, Jose Andres, Besora, Sarah, Hughes, Stella, Gray, Orla, Grigoriadis, Nikolaos, Piroska, Imre, Rozsa, Csilla, Kasa, Krisztian, Simo, Magdolna, Kovacs, Krisztina, Sas, Attila, Dobos, Eniko, Rajda, Cecilia, McGuigan, Chris, Mason, Deborah, Schepel, Jan, Alkhaboori, Jabir, Rio, Maria Edite, Mihaela, Simu, Al-Harbi, Talal, Altintas, Ayse, Kister, Ilya, Marriott, Mark, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Diamanti, Matteo, Chisari, Clara, Toscano, Simona, Salvatore, Lo Fermo, Larochelle, Catherine, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hupperts, Raymond, Olascoaga, Javier, Saiz, Albert, Zivadinov, Robert, Benedict, Ralph, Verheul, Freek, Fabis-Pedrini, Marzena, Mrabet, Saloua, Garber, Justin, Sanchez-Menoyo, Jose Luis, Aguera-Morales, Eduardo, Blanco, Yolanda, Al-Asmi, Abdullah, Weinstock-Guttman, Bianca, Fragoso, Yara, de Gans, Koen, and Kermode, Allan

Subjects
Human medicine
Abstract

you are agreeing to our Cookie Policy | Continue JAMA Network HomeJAMA Neurology This Issue Views 2,357 Citations 0 60 Full Text Share Comment Original Investigation May 15, 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Tomas Kalincik, MD, PhD1,2; Sifat Sharmin, PhD1,2; Izanne Roos, MBChB, PhD1,2; Mark S. Freedman, MD3; Harold Atkins, MD4; Joachim Burman, MD, PhD5; Jennifer Massey, MBBS, PhD6,7; Ian Sutton, MBBS, PhD6,8; Barbara Withers, MD, PhD7,9; Richard Macdonell, MD, PhD10,11; Andrew Grigg, MD, PhD11,12; Øivind Torkildsen, MD, PhD13; Lars Bo, MD, PhD13; Anne Kristine Lehmann, MD, PhD14; Eva Kubala Havrdova, MD, PhD15; Eva Krasulova, MD, PhD15; Marek Trněný, MD, PhD16; Tomas Kozak, MD, PhD17; Anneke van der Walt, MBBS, PhD18,19; Helmut Butzkueven, MBBS, PhD18,19; Pamela McCombe, MBBS20,21; Olga Skibina, MBBS18,22,23; Jeannette Lechner-Scott, MD, PhD24,25; Barbara Willekens, MD, PhD26,27; Elisabetta Cartechini, MD28; Serkan Ozakbas, MD29; Raed Alroughani, MD30; Jens Kuhle, MD, PhD31; Francesco Patti, MD32,33; Pierre Duquette, MD34; Alessandra Lugaresi, MD, PhD35,36; Samia J. Khoury, MD, PhD37; Mark Slee, MD, PhD38; Recai Turkoglu, MD39; Suzanne Hodgkinson, MD40; Nevin John, MD, PhD41,42; Davide Maimone, MD43; Maria Jose Sa, MD44; Vincent van Pesch, MD, PhD45,46; Oliver Gerlach, MD, PhD47,48; Guy Laureys, MD49; Liesbeth Van Hijfte, MD49; Rana Karabudak, MD50; Daniele Spitaleri, MD51; Tunde Csepany, MD, PhD52; Riadh Gouider, MD53,54; Tamara Castillo-Triviño, MD55; Bruce Taylor, MD, PhD56,57; Basil Sharrack, MD, PhD58; John A. Snowden, MD, PhD59; and the MSBase Study Group Collaborators; and the MSBase Study Group Authors Author Affiliations JAMA Neurol. 2023;80(7):702-713. doi:10.1001/jamaneurol.2023.1184 editorial comment iconEditorial Comment Key Points Question What is the comparative effectiveness of autologous hematopoietic stem cell transplant (AHSCT) vs individual most potent disease-modifying therapies for relapsing-remitting multiple sclerosis (MS), such as natalizumab or ocrelizumab? Findings In this observational comparative effectiveness study of 4915 individuals using a composite cohort from specialized MS centers and the MSBase international registry, the effectiveness of AHSCT was compared with 1 medium-efficacy and 2 high-efficacy disease-modifying therapies (fingolimod, natalizumab, and ocrelizumab) in patients with relapsing-remitting MS, high frequency of relapses, and moderate disability. Over 5 years, AHSCT was associated with substantially lower relapse rate than fingolimod and marginally lower relapse rate than natalizumab and was also associated with a higher rate of recovery from disability compared with fingolimod and natalizumab, but no evidence of difference in clinical outcomes between AHSCT and ocrelizumab was found at 3-year follow-up. Meaning The results indicate that in relapsing-remitting MS, the clinical effectiveness of AHSCT is considerably superior to fingolimod and marginally superior to natalizumab. Abstract Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, Setting, and Participants This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.

Published
2023

20. sj-docx-1-msj-10.1177_13524585231151951 – Supplemental material for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Daruwalla, Cyrus, Shaygannejad, Vahid, Ozakbas, Serkan, Havrdova, Eva Kubala, Horakova, Dana, Alroughani, Raed, Boz, Cavit, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J, Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Buzzard, Katherine, Grammond, Pierre, Karabudak, Rana, van der Walt, Anneke, Butzkueven, Helmut, Maimone, Davide, Lechner-Scott, Jeannette, Soysal, Aysun, John, Nevin, Prevost, Julie, Spitaleri, Daniele, Ramo-Tello, Cristina, Gerlach, Oliver, Iuliano, Gerardo, Foschi, Matteo, Ampapa, Radek, van Pesch, Vincent, Barnett, Michael, Shalaby, Nevin, D’hooghe, Marie, Kuhle, Jens, Sa, Maria Jose, Fabis-Pedrini, Marzena, Kermode, Allan, Mrabet, Saloua, Gouider, Riadh, Hodgkinson, Suzanne, Laureys, Guy, Van Hijfte, Liesbeth, Macdonell, Richard, Oreja-Guevara, Celia, Cristiano, Edgardo, McCombe, Pamela, Sanchez-Menoyo, Jose Luis, Singhal, Bhim, Blanco, Yolanda, Hughes, Stella, Garber, Justin, Solaro, Claudio, McGuigan, Chris, Taylor, Bruce, de Gans, Koen, Habek, Mario, Al-Asmi, Abdullah, Mihaela, Simu, Castillo Triviño, Tamara, Al-Harbi, Talal, Rojas, Juan Ignacio, Gray, Orla, Khurana, Dheeraj, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Inshasi, Jihad, Oh, Jiwon, Aguera-Morales, Eduardo, Fragoso, Yara, Moore, Fraser, Shaw, Cameron, Baghbanian, Seyed Mohammad, Shuey, Neil, Willekens, Barbara, Hardy, Todd A, Decoo, Danny, sempere, Angel Perez, Field, Deborah, Wynford-Thomas, Ray, Cunniffe, Nick G, Roos, Izanne, Malpas, Charles B, Coles, Alasdair J, Kalincik, Tomas, and Brown, J William L

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585231151951 for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis by Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D’hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Triviño, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A Hardy, Danny Decoo, Angel Perez sempere, Deborah Field, Ray Wynford-Thomas, Nick G Cunniffe, Izanne Roos, Charles B Malpas, Alasdair J Coles, Tomas Kalincik and J William L Brown in Multiple Sclerosis Journal

Published
2023
Full Text
View/download PDF

21. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Sánchez, Marina M, Ozakbas, Serkan, Horakova, Dana, Havrdova, Eva K, Patti, Francesco, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Boz, Cavit, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Weinstock-Guttman, Bianca, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Amato, Maria Pia, Karabudak, Rana, Grand'Maison, Francois, Khoury, Samia J, Grammond, Pierre, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Turkoglu, Recai, Altintas, Ayse, Maimone, Davide, Kermode, Allan, Shalaby, Nevin, Pesch, Vincent V, Butler, Ernest, Sidhom, Youssef, Gouider, Riadh, Mrabet, Saloua, Gerlach, Oliver, Soysal, Aysun, Barnett, Michael, Kuhle, Jens, Hughes, Stella, Maria J, Sa, Hodgkinson, Suzanne, Oreja-Guevara, Celia, Ampapa, Radek, Petersen, Thor, Ramo-Tello, Cristina, Spitaleri, Daniele, Mccombe, Pamela, Taylor, Bruce, Prevost, Julie, Foschi, Matteo, Slee, Mark, Mcguigan, Chris, Laureys, Guy, Hijfte, Liesbeth V, de Gans, Koen, Solaro, Claudio, Jiwon, Oh, Macdonell, Richard, Aguera-Morales, Eduardo, Singhal, Bhim, Gray, Orla, Garber, Justin, Wijmeersch, Bart V, Simu, Mihaela, Triviño, Tamara C, Sanchez-Menoyo, Jose L, Khurana, Dheeraj, Al-Asmi, Abdullah, Al-Harbi, Talal, Deri, Norma, Fragoso, Yara, Lalive, Patrice H, Sinnige, L G F, Shaw, Cameron, Shuey, Neil, Csepany, Tunde, Sempere, Angel P, Moore, Fraser, Decoo, Danny, Willekens, Barbara, Gobbi, Claudio, Massey, Jennifer, Hardy, Todd, Parratt, John, and Kalincik, Tomas

Subjects
secondary progressive multiple sclerosis, health expenditure, disease-modifying therapy, geography, latitude
Published
2023

22. External validation of a clinical prediction model in multiple sclerosis

Author

Moradi, Nahid, primary, Sharmin, Sifat, additional, Malpas, Charles B, additional, Shaygannejad, Vahid, additional, Terzi, Murat, additional, Boz, Cavit, additional, Yamout, Bassem, additional, Khoury, Samia J, additional, Turkoglu, Recai, additional, Karabudak, Rana, additional, Shalaby, Nevin, additional, Soysal, Aysun, additional, Altıntaş, Ayşe, additional, Inshasi, Jihad, additional, Al-Harbi, Talal, additional, Alroughani, Raed, additional, and Kalincik, Tomas, additional

Published
2022
Full Text
View/download PDF

23. Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study

Author

De Brouwer, Edward, primary, Becker, Thijs, additional, Werthen-Brabants, Lorin, additional, Dewulf, Pieter, additional, Iliadis, Dimitrios, additional, Dekeyser, Cathérine, additional, Laureys, Guy, additional, Van Wijmeersch, Bart, additional, Popescu, Veronica, additional, Dhaene, Tom, additional, Deschrijver, Dirk, additional, Waegeman, Willem, additional, De Baets, Bernard, additional, Stock, Michiel, additional, Horakova, Dana, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Alroughani, Raed, additional, Grand’Maison, Francois, additional, Skibina, Olga, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Gerlach, Oliver, additional, Khoury, Samia J., additional, Cartechini, Elisabetta, additional, Van Pesch, Vincent, additional, Sa, Maria Jose, additional, Weinstock-Guttman, Bianca, additional, Blanco, Yolanda, additional, Ampapa, Radek, additional, Spitaleri, Daniele, additional, Solaro, Claudio, additional, Maimone, Davide, additional, Soysal, Aysun, additional, Iuliano, Gerardo, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose Luis, additional, van der Walt, Anneke, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Altintas, Ayse, additional, Al-Asmi, Abdullah, additional, de Gans, Koen, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Hodgkinson, Suzanne, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Taylor, Bruce, additional, Gray, Orla, additional, Lalive, Patrice, additional, Rozsa, Csilla, additional, McGuigan, Chris, additional, Kermode, Allan, additional, Perez sempere, Angel, additional, Mihaela, Simu, additional, Simo, Magdolna, additional, Hardy, Todd, additional, Decoo, Danny, additional, Hughes, Stella, additional, Grigoriadis, Nikolaos, additional, Sas, Attila, additional, Vella, Norbert, additional, Moreau, Yves, additional, and Peeters, Liesbet, additional

Published
2022
Full Text
View/download PDF

25. Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis

Author

Alzahrani, Musa, primary, Al Turki, Saeed, additional, Al Rajban, Waleed, additional, Alshalati, Fatimah, additional, Almodaihsh, Fahad, additional, Abuelgasim, Khadega A., additional, Alahmari, Bader, additional, Al Bogami, Thamer, additional, Ali, Osama, additional, Al Harbi, Talal, additional, AlBalwi, Mohammed A., additional, Alotaibi, Maram, additional, Aleem, Aamer, additional, Al Asker, Ahmed, additional, and Al Mugairi, Areej, additional

Published
2022
Full Text
View/download PDF

26. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Author

Sharmin, Sifat, primary, Bovis, Francesca, additional, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Trojano, Maria, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grand'Maison, Francois, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Terzi, Murat, additional, Gerlach, Oliver, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Shaygannejad, Vahid, additional, van Pesch, Vincent, additional, Cartechini, Elisabetta, additional, Kappos, Ludwig, additional, Lechner‐Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Turkoglu, Recai, additional, Solaro, Claudio, additional, Iuliano, Gerardo, additional, Granella, Franco, additional, Van Wijmeersch, Bart, additional, Spitaleri, Daniele, additional, Slee, Mark, additional, McCombe, Pamela, additional, Prevost, Julie, additional, Ampapa, Radek, additional, Ozakbas, Serkan, additional, Sanchez‐Menoyo, Jose Luis, additional, Soysal, Aysun, additional, Vucic, Steve, additional, Petersen, Thor, additional, de Gans, Koen, additional, Butler, Ernest, additional, Hodgkinson, Suzanne, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Cristiano, Edgardo, additional, Castillo‐Triviño, Tamara, additional, Saladino, Maria Laura, additional, Barnett, Michael, additional, Moore, Fraser, additional, Rozsa, Csilla, additional, Yamout, Bassem, additional, Skibina, Olga, additional, van der Walt, Anneke, additional, Buzzard, Katherine, additional, Gray, Orla, additional, Hughes, Stella, additional, Sempere, Angel Perez, additional, Singhal, Bhim, additional, Fragoso, Yara, additional, Shaw, Cameron, additional, Kermode, Allan, additional, Taylor, Bruce, additional, Simo, Magdolna, additional, Shuey, Neil, additional, Al‐Harbi, Talal, additional, Macdonell, Richard, additional, Dominguez, Jose Andres, additional, Csepany, Tunde, additional, Sirbu, Carmen Adella, additional, Sormani, Maria Pia, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional

Published
2022
Full Text
View/download PDF

27. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Rojas, Juan Ignacio, Gray, Orla, Khurana, Dheeraj, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Inshasi, Jihad, Oh, Jiwon, Aguera-Morales, Eduardo, Fragoso, Yara, Moore, Fraser, Shaw, Cameron, Baghbanian, Seyed Mohammad, Shuey, Neil, Willekens, Barbara, Hardy, Todd A., Decoo, Danny, Sempere, Angel Perez, Field, Deborah, Wynford-Thomas, Ray, Cunniffe, Nick G., Roos, Izanne, Malpas, Charles B., Coles, Alasdair J., Kalincik, Tomas, Brown, J. William L., MSBase Study Grp, MSBase Study Grp, Shaygannejad, Vahid, Daruwalla, Cyrus, ÖZAKBAŞ, SERKAN, Havrdova, Eva Kubala, Horakova, Dana, Alroughani, Raed, BOZ, CAVİT, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J., Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Buzzard, Katherine, Grammond, Pierre, Karabudak, Rana, van der Walt, Anneke, Butzkueven, Helmut, Maimone, Davide, Lechner-Scott, Jeannette, Soysal, Aysun, John, Nevin, Prevost, Julie, Spitaleri, Daniele, Ramo-Tello, Cristina, Gerlach, Oliver, Iuliano, Gerardo, Foschi, Matteo, Ampapa, Radek, van Pesch, Vincent, Barnett, Michael, Shalaby, Nevin, D'hooghe, Marie, Kuhle, Jens, Sa, Maria Jose, Fabis-Pedrini, Marzena, Kermode, Allan, Mrabet, Saloua, Gouider, Riadh, Hodgkinson, Suzanne, Laureys, Guy, Van Hijfte, Liesbeth, Macdonell, Richard, Oreja-Guevara, Celia, Cristiano, Edgardo, McCombe, Pamela, Sanchez-Menoyo, Jose Luis, Singhal, Bhim, Blanco, Yolanda, Hughes, Stella, Garber, Justin, Solaro, Claudio, McGuigan, Chris, Taylor, Bruce, de Gans, Koen, Habek, Mario, Al-Asmi, Abdullah, Mihaela, Simu, Castillo Trivino, Tamara, Al-Harbi, Talal, MSBase Study Group, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Faculty of Medicine and Pharmacy, Daruwalla, Cyrus [0000-0002-2329-5329], Shaygannejad, Vahid [0000-0001-5511-509X], Horakova, Dana [0000-0003-1915-0036], Alroughani, Raed [0000-0001-5436-5804], Patti, Francesco [0000-0002-6923-0846], Lugaresi, Alessandra [0000-0003-2902-5589], Eichau, Sara [0000-0001-9159-3128], Duquette, Pierre [0000-0001-7231-1754], Sajedi, Seyed Aidin [0000-0002-6704-9787], van der Walt, Anneke [0000-0002-4278-7003], Lechner-Scott, Jeannette [0000-0002-3850-447X], Barnett, Michael [0000-0002-2156-8864], Oreja-Guevara, Celia [0000-0002-9221-5716], Habek, Mario [0000-0002-3360-1748], Castillo Triviño, Tamara [0000-0002-9249-3185], Inshasi, Jihad [0000-0001-5892-751X], Oh, Jiwon [0000-0001-5519-6088], Fragoso, Yara [0000-0001-8726-089X], Baghbanian, Seyed Mohammad [0000-0002-8138-7504], Hardy, Todd A [0000-0003-4145-3172], Decoo, Danny [0000-0001-7689-3114], Roos, Izanne [0000-0003-0371-3666], Kalincik, Tomas [0000-0003-3778-1376], Brown, J William L [0000-0002-7737-5834], Apollo - University of Cambridge Repository, and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire

Subjects
Neuroscience(all), Multiple sclerosis, prognosis, multiple sclerosis, Prognosis, Multiple Sclerosis, Relapsing-Remitting, Neurology, Recurrence, Medicine and Health Sciences, Humans, Human medicine, Neurology (clinical)
Abstract

Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS. Methods: We redefined mild relapses in MSBase as ‘non-disabling’, and moderate or severe relapses as ‘disabling’. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. Results: People who experienced non-disabling relapses within 2 years of RRMS diagnosis accumulated more disability than those with no early relapses if they were untreated ( n = 285 vs 4717; hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.00–1.68) or given platform DMTs ( n = 1074 vs 7262; HR = 1.33, 95% CI = 1.15–1.54), but not if given high-efficacy DMTs ( n = 572 vs 3534; HR = 0.90, 95% CI = 0.71–1.13) during follow-up. Differences in disability accumulation between those with early non-disabling relapses and those with early disabling relapses were not confirmed statistically. Conclusion: This study suggests that early non-disabling relapses are associated with a higher risk of disability accumulation than no early relapses in RRMS. This risk may be mitigated by high-efficacy DMTs. Therefore, non-disabling relapses should be considered when making treatment decisions.

Published
2023
Full Text
View/download PDF

28. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Gerlach, Oliver, Alroughani, Raed, Boz, Cavit, Shaygannejad, Vahid, van Pesch, Vincent, Cartechini, Elisabetta, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Iuliano, Gerardo, Granella, Franco, Van Wijmeersch, Bart, Spitaleri, Daniele, Slee, Mark, McCombe, Pamela, Prevost, Julie, Ampapa, Radek, Ozakbas, Serkan, Sanchez-Menoyo, Jose Luis, Soysal, Aysun, Vucic, Steve, Petersen, Thor, de Gans, Koen, Butler, Ernest, Hodgkinson, Suzanne, Sidhom, Youssef, Gouider, Riadh, Cristiano, Edgardo, Castillo-Triviño, Tamara, Saladino, Maria Laura, Barnett, Michael, Moore, Fraser, Rozsa, Csilla, Yamout, Bassem, Skibina, Olga, van der Walt, Anneke, Buzzard, Katherine, Gray, Orla, Hughes, Stella, Sempere, Angel Perez, Singhal, Bhim, Fragoso, Yara, Shaw, Cameron, Kermode, Allan, Taylor, Bruce, Simo, Magdolna, Shuey, Neil, Al-Harbi, Talal, Macdonell, Richard, Dominguez, Jose Andres, Csepany, Tunde, Sirbu, Carmen Adella, Sormani, Maria Pia, Butzkueven, Helmut, Kalincik, Tomas, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Gerlach, Oliver, Alroughani, Raed, Boz, Cavit, Shaygannejad, Vahid, van Pesch, Vincent, Cartechini, Elisabetta, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Iuliano, Gerardo, Granella, Franco, Van Wijmeersch, Bart, Spitaleri, Daniele, Slee, Mark, McCombe, Pamela, Prevost, Julie, Ampapa, Radek, Ozakbas, Serkan, Sanchez-Menoyo, Jose Luis, Soysal, Aysun, Vucic, Steve, Petersen, Thor, de Gans, Koen, Butler, Ernest, Hodgkinson, Suzanne, Sidhom, Youssef, Gouider, Riadh, Cristiano, Edgardo, Castillo-Triviño, Tamara, Saladino, Maria Laura, Barnett, Michael, Moore, Fraser, Rozsa, Csilla, Yamout, Bassem, Skibina, Olga, van der Walt, Anneke, Buzzard, Katherine, Gray, Orla, Hughes, Stella, Sempere, Angel Perez, Singhal, Bhim, Fragoso, Yara, Shaw, Cameron, Kermode, Allan, Taylor, Bruce, Simo, Magdolna, Shuey, Neil, Al-Harbi, Talal, Macdonell, Richard, Dominguez, Jose Andres, Csepany, Tunde, Sirbu, Carmen Adella, Sormani, Maria Pia, Butzkueven, Helmut, and Kalincik, Tomas

Abstract

The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.

Published
2022

29. sj-docx-1-msj-10.1177_13524585221136036 – Supplemental material for External validation of a clinical prediction model in multiple sclerosis

Author

Moradi, Nahid, Sharmin, Sifat, Malpas, Charles B, Shaygannejad, Vahid, Terzi, Murat, Boz, Cavit, Yamout, Bassem, Khoury, Samia J, Turkoglu, Recai, Karabudak, Rana, Shalaby, Nevin, Soysal, Aysun, Altıntaş, Ayşe, Inshasi, Jihad, Al-Harbi, Talal, Alroughani, Raed, and Kalincik, Tomas

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221136036 for External validation of a clinical prediction model in multiple sclerosis by Nahid Moradi, Sifat Sharmin, Charles B Malpas, Vahid Shaygannejad, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Recai Turkoglu, Rana Karabudak, Nevin Shalaby, Aysun Soysal, Ayşe Altıntaş, Jihad Inshasi, Talal Al-Harbi, Raed Alroughani and Tomas Kalincik in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

31. External validation of a clinical prediction model in multiple sclerosis.

Author

Moradi, Nahid, Sharmin, Sifat, Malpas, Charles B, Shaygannejad, Vahid, Terzi, Murat, Boz, Cavit, Yamout, Bassem, Khoury, Samia J, Turkoglu, Recai, Karabudak, Rana, Shalaby, Nevin, Soysal, Aysun, Altıntaş, Ayşe, Inshasi, Jihad, Al-Harbi, Talal, Alroughani, Raed, and Kalincik, Tomas

Subjects
PREDICTION models, MULTIPLE sclerosis, TERMINATION of treatment, MEDICAL registries, DISEASE relapse
Abstract

Background: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). Objective: We aimed to validate a previously published predictive model of individual treatment response using a non-overlapping cohort from the Middle East. Methods: We interrogated the MSBase registry for patients who were not included in the initial model development. These patients had relapsing MS or clinically isolated syndrome, a recorded date of disease onset, disability and dates of disease modifying therapy, with sufficient follow-up pre- and post-baseline. Baseline was the visit at which a new disease modifying therapy was initiated, and which served as the start of the predicted period. The original models were used to translate clinical information into three principal components and to predict probability of relapses, disability worsening or improvement, conversion to secondary progressive MS and treatment discontinuation as well as changes in the area under disability-time curve (ΔAUC). Prediction accuracy was assessed using the criteria published previously. Results: The models performed well for predicting the risk of disability worsening and improvement (accuracy: 81%–96%) and performed moderately well for predicting the risk of relapses (accuracy: 73%–91%). The predictions for ΔAUC and risk of treatment discontinuation were suboptimal (accuracy < 44%). Accuracy for predicting the risk of conversion to secondary progressive MS ranged from 50% to 98%. Conclusion: The previously published models are generalisable to patients with a broad range of baseline characteristics in different geographic regions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Clinical course of myeloproliferative leukaemia virus oncogene ( MPL ) mutation‐associated familial thrombocytosis: a review of 64 paediatric and adult patients

Author

Al‐Harbi, Talal, primary, Al‐Zahrani, Mohsen, additional, Al‐Balwi, Mohammed, additional, Al‐Hazmi, Aiman, additional, Alsuhaibani, Ahmed, additional, Aljafn, Nahed, additional, Alsumari, Fatimah, additional, Aleshaiwi, Latefah, additional, Alsuhibani, Alanoud, additional, Alqasim, Ohoud, additional, and Ahmad, Naveed, additional

Published
2021
Full Text
View/download PDF

42. Transcranial magnetic stimulation for migraine: clinical effects

Author

Clarke, Beverley M., Upton, Adrian R.M., Kamath, Mark V., Al-Harbi, Talal, and Castellanos, Claudia M.

Subjects
Magnetic brain stimulation -- Health aspects, Magnetic brain stimulation -- Research, Migraine -- Care and treatment, Migraine -- Research, Health
Published
2006

43. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Author

Diouf, Ibrahima, primary, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Ayuso, Guillermo Izquierdo, additional, Madueño, Sara Eichau, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Butzkueven, Helmut, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Van Pesch, Vincent, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Christopher, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria Jose, additional, Kappos, Ludwig, additional, Ramo-Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele Litterio A., additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, Verheul, Freek, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Skibina, Olga, additional, Prevost, Julie, additional, Sinnige, L, additional, Sanchez-Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Kister, Ilya, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

44. A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon β-1a

Author

Al Jumah, Mohammed, primary, Kojan, Suleiman, additional, Alroughani, Raed, additional, Cupler, Edward, additional, Bohlega, Saeed, additional, Daif, Abdulkader, additional, Al Mujalli, Mousa, additional, Al Harbi, Talal, additional, El Tamawy, Mohamed, additional, Ashour, Samia, additional, Mhiri, Chokri, additional, Gouider, Riadh, additional, Jawhary, Ayah, additional, El Boghdady, Ahmed, additional, and Hussein, Mohamed, additional

Published
2021
Full Text
View/download PDF

47. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

Author

Diouf, Ibrahima, Malpas, Charles B, Sharmin, Sifat, Roos, Izanne, Horakova, Dana, Kubala Havrdova, Eva, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Yamout, Bassem, Altintas, Ayse, Gerlach, Oliver, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Karabudak, Rana, Iuliano, Gerardo, McGuigan, Christopher, Cartechini, Elisabetta, Hughes, Stella, Sa, Maria Jose, Solaro, Claudio, Kappos, Ludwig, Hodgkinson, Suzanne, Slee, Mark, Granella, Franco, de Gans, Koen, McCombe, Pamela A, Ampapa, Radek, van der Walt, Anneke, Butzkueven, Helmut, Sánchez-Menoyo, José Luis, Vucic, Steve, Laureys, Guy, Sidhom, Youssef, Gouider, Riadh, Castillo-Trivino, Tamara, Gray, Orla, Aguera-Morales, Eduardo, Al-Asmi, Abdullah, Shaw, Cameron, Al-Harbi, Talal M, Csepany, Tunde, Sempere, Angel P, Treviño Frenk, Irene, Stuart, Elizabeth A, and Kalincik, Tomas

Abstract

BackgroundSimultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. Here we emulate a randomised trial simultaneously comparing the effectiveness of six commonly used therapies over 5 years.MethodsData from 74 centres in 35 countries were sourced from MSBase. For each patient, the first eligible intervention was analysed, censoring at change/discontinuation of treatment. The compared interventions included natalizumab, fingolimod, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate and no treatment. Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement.Results23 236 eligible patients were diagnosed with RRMS or clinically isolated syndrome. Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). Further, natalizumab (HR=0.43, 95% CI=0.32 to 0.56) showed a superior ATE in reducing disability worsening and in disability improvement (HR=1.32, 95% CI=1.08 to 1.60). The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability.ConclusionsThe effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously.

Published
2023
Full Text
View/download PDF

48. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

Author

Sharmin, Sifat, primary, Bovis, Francesca, additional, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Ayuso, Guillermo Izquierdo, additional, Eichau, Sara, additional, Trojano, Maria, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grand’Maison, Francois, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Terzi, Murat, additional, Hupperts, R.M.M., additional, Alroughani, Raed, additional, Boz, Cavit, additional, Shaygannejad, Vijay, additional, Van Pesch, Vincent, additional, Kappos, Ludwig, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Turkoglu, Recai, additional, Solaro, Claudio, additional, Ramo-Tello, Cristina, additional, Iuliano, Gerardo, additional, Granella, Franco, additional, Van Wijmeersch, Bart, additional, Spitaleri, Daniele Litterio A., additional, Bolanos, Ricardo Fernandez, additional, Slee, Mark, additional, McCombe, Pamela, additional, Prevost, Julie, additional, Ampapa, Radek, additional, Ozakbas, Serkan, additional, Sanchez-Menoyo, Jose Luis, additional, Soysal, Aysun, additional, Vucic, Ostoja (Steve), additional, Petersen, Thor, additional, Verheul, Freek, additional, Butler, Ernest, additional, Hodgkinson, Suzanne, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Cristiano, Edgardo, additional, Urtaza, Francisco Javier Olascoaga, additional, Saladino, Maria Laura, additional, Barnett, Michael, additional, Deri, Norma, additional, Moore, Fraser, additional, Rozsa, Csilla, additional, Yamout, Bassem, additional, Skibina, Olga, additional, Gray, Orla, additional, Campbell, Jamie, additional, Sempere, Angel, additional, Singhal, Bhim, additional, Fragoso, Yara, additional, Shaw, Cameron, additional, Kermode, Allan, additional, Petkovska-Boskova, Tatjana, additional, Taylor, Bruce, additional, Simo, Magdolna, additional, Vella, Norbert, additional, Shuey, Neil, additional, Alkhaboori, Jabir, additional, Al-Harbi, Talal, additional, Macdonell, Richard, additional, Dominguez, Jose Andres, additional, Kister, Ilya, additional, Csepany, Tunde, additional, Vrech, Carlos, additional, Kovacs, Krisztina, additional, Sirbu, Carmen Adella, additional, Hughes, Stella, additional, Sormani, Maria Pia, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional

Published
2020
Full Text
View/download PDF

49. Development of PCCNN-Based Network Intrusion Detection System for EDGE Computing.

Author

Haq, Mohd Anul, Rahim Khan, Mohd Abdul, and AL-Harbi, Talal

Subjects
EDGE computing, CONVOLUTIONAL neural networks, COMPUTER systems, GSM communications, DEEP learning, PRINCIPAL components analysis, DENIAL of service attacks
Abstract

Intrusion Detection System (IDS) plays a crucial role in detecting and identifying the DoS and DDoS type of attacks on IoT devices. However, anomaly-based techniques do not provide acceptable accuracy for efficacious intrusion detection. Also, we found many difficulty levels when applying IDS to IoT devices for identifying attempted attacks. Given this background, we designed a solution to detect intrusions using the Convolutional Neural Network (CNN) for Enhanced Data rates for GSM Evolution (EDGE) Computing.We created two separate categories to handle the attack and non-attack events in the system. The findings of this study indicate that this approach was significantly effective. We attempted both multiclass and binary classification. In the case of binary, we clustered all malicious traffic data in a single class. Also, we developed 13 layers of Sequential 1-D CNN for IDS detection and assessed them on the public dataset NSL-KDD. Principal Component Analysis (PCA) was implemented to decrease the size of the feature vector based on feature extraction and engineering. The approach proposed in the current investigation obtained accuracies of 99.34% and 99.13% for binary and multiclass classification, respectively, for the NSL-KDD dataset. The experimental outcomes showed that the proposed Principal Component-based Convolution Neural Network (PCCNN) approach achieved greater precision based on deep learning and has potential use in modern intrusion detection for IoT systems. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Rare neurological manifestations in a Saudi Arabian patient with Ehlers–Danlos syndrome and a novel homozygous variant in the TNXB gene.

Author

Al‐Harbi, Talal M., Al‐Rammah, Haya, Al‐Zahrani, Naif, Liu, Yichuan, Sleiman, Patrick M. A., Dridi, Walid, and Hakonarson, Hakon

Abstract

We report a 38‐year‐old Saudi male with Ehlers–Danlos Syndrome (EDS). The patient presented with rare and unusual neurological manifestations, including but not limited to ophthalmoplegia and myopathic pattern on his electromyography. In addition to hand weakness, there was skin hyperextensibility, joint hyperflexibility, and frontal baldness. Next‐generation sequencing was performed on target exon sequences, using whole exome sequencing and Burrows–Wheeler Aligner for alignment/base calling. Genome Analysis Toolkit and reference genome Homo sapiens (UCSC hg19) were used for sequence processing and analysis. Variant classification was done according to standard international recommendations. A novel homozygous variant, NM_019105.6: c.8488C>T p.(Gln2830*), was detected in the TNXB gene. This variant is not reported in the literature nor dbSNP or gnomAD databases. Additionally, this variant is predicted to create a premature stop codon and produce a truncated protein or nonsense‐mediated mRNA decay. Hence, it is classified as a likely pathogenic variant. The same point variant was found in a heterozygous state in the patient's father and sister. Both presented with milder symptoms associated with Ehlers–Danlos syndromes and heritable connective tissue disorders. Therefore, the patient was diagnosed as a tenascin‐X (TNX) deficient type of EDS known as classical‐like Ehlers–Danlos syndrome. TNX deficient patients may present with clinical and electrophysiological manifestations that are unusual in EDS like frontal baldness, ophthalmoplegia, and myotonia, which mimic myotonic dystrophy type I. Clinicians should be aware of the potential overlap of symptoms among these two diseases to ensure correct diagnosis is made. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results